Literature DB >> 19015566

Guidelines for the management of chronic kidney disease.

Adeera Levin1, Brenda Hemmelgarn, Bruce Culleton, Sheldon Tobe, Philip McFarlane, Marcel Ruzicka, Kevin Burns, Braden Manns, Colin White, Francoise Madore, Louise Moist, Scott Klarenbach, Brendan Barrett, Robert Foley, Kailash Jindal, Peter Senior, Neesh Pannu, Sabin Shurraw, Ayub Akbari, Adam Cohn, Martina Reslerova, Vinay Deved, David Mendelssohn, Gihad Nesrallah, Joanne Kappel, Marcello Tonelli.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 19015566      PMCID： PMC2582781          DOI： 10.1503/cmaj.080351

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  66 in total

Review 1.  A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States.

Authors:  Braden Manns; Lesley Stevens; Dana Miskulin; William F Owen; Wolfgang C Winkelmayer; Marcello Tonelli
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

Review 2.  Low protein diets for chronic kidney disease in non diabetic adults.

Authors:  D Fouque; M Laville; J P Boissel
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 3.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  S Salpeter; E Greyber; G Pasternak; E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 4.  Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology.

Authors:  Kailash Jindal; Christopher T Chan; Clement Deziel; David Hirsch; Steven D Soroka; Marcello Tonelli; Bruce F Culleton
Journal:  J Am Soc Nephrol       Date:  2006-03       Impact factor: 10.121

5.  Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors.

Authors:  K C Mange; M M Joffe; H I Feldman
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

6.  Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data.

Authors: 
Journal:  Ann Intern Med       Date:  2001-03-06       Impact factor: 25.391

Review 7.  Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'.

Authors:  J D Lalau; J M Race
Journal:  Diabetes Obes Metab       Date:  2001-06       Impact factor: 6.577

8.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Authors:  Geoffrey A Block; Preston S Klassen; J Michael Lazarus; Norma Ofsthun; Edmund G Lowrie; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

Review 9.  Effect of pravastatin on cardiovascular events in people with chronic kidney disease.

Authors:  Marcello Tonelli; Chris Isles; Gary C Curhan; Andrew Tonkin; Marc A Pfeffer; James Shepherd; Frank M Sacks; Curt Furberg; Stuart M Cobbe; John Simes; Timothy Craven; Malcolm West
Journal:  Circulation       Date:  2004-09-13       Impact factor: 29.690

10.  Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization.

Authors:  Douglas S Keith; Gregory A Nichols; Christina M Gullion; Jonathan Betz Brown; David H Smith
Journal:  Arch Intern Med       Date:  2004-03-22
View more
  122 in total

1.  Quality indicators for the detection and management of chronic kidney disease in primary care in Canada derived from a modified Delphi panel approach.

Authors:  Karen Tu; Lindsay Bevan; Katie Hunter; Jess Rogers; Jacqueline Young; Gihad Nesrallah
Journal:  CMAJ Open       Date:  2017-01-25

Review 2.  Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease.

Authors:  Rikki M Tanner; Todd M Brown; Paul Muntner
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

3.  Progress and promise in the management of chronic kidney disease.

Authors:  Garabed Eknoyan
Journal:  CMAJ       Date:  2008-11-18       Impact factor: 8.262

4.  Standards of clinical practice for renal pharmacists.

Authors:  Colette B Raymond; Lori D Wazny; Amy R Sood
Journal:  Can J Hosp Pharm       Date:  2013-11

5.  Motivational interviewing promotes adherence and improves wellbeing in pre-dialysis patients with advanced chronic kidney disease.

Authors:  Helena García-Llana; Eduardo Remor; Gloria del Peso; Olga Celadilla; Rafael Selgas
Journal:  J Clin Psychol Med Settings       Date:  2014-03

6.  Impact of kidney function and urinary protein excretion on intima-media thickness in Japanese patients with type 2 diabetes.

Authors:  Yusuke Nakade; Tadashi Toyama; Kengo Furuichi; Shinji Kitajima; Yoshiyasu Miyajima; Mihiro Fukamachi; Akihiro Sagara; Yasuyuki Shinozaki; Akinori Hara; Miho Shimizu; Yasunori Iwata; Hiroyasu Oe; Mikio Nagahara; Hiroshi Horita; Yoshio Sakai; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2015-02-03       Impact factor: 2.801

7.  Zinc deficiency induces hypertension by promoting renal Na+ reabsorption.

Authors:  Clintoria R Williams; Monisha Mistry; Aswathy M Cheriyan; Jasmine M Williams; Meagan K Naraine; Carla L Ellis; Rickta Mallick; Abinash C Mistry; Jennifer L Gooch; Benjamin Ko; Hui Cai; Robert S Hoover
Journal:  Am J Physiol Renal Physiol       Date:  2019-01-16

8.  Learning from marketing: Rapid development of medication messages that engage patients.

Authors:  Veronica Yank; Erika Tribett; Lydia Green; Jasmine Pettis
Journal:  Patient Educ Couns       Date:  2015-03-14

Review 9.  Hypertension and chronic kidney disease: controversies in pathogenesis and treatment.

Authors:  J L Pirkle; B I Freedman
Journal:  Minerva Urol Nefrol       Date:  2013-03       Impact factor: 3.720

10.  Adherence to a healthy lifestyle and all-cause mortality in CKD.

Authors:  Ana C Ricardo; Magdalena Madero; Wei Yang; Cheryl Anderson; Matthew Menezes; Michael J Fischer; Mary Turyk; Martha L Daviglus; James P Lash
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-21       Impact factor: 8.237
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.